Table 1.

Basic demographics split by 1st diagnosis of primary breast cancer (PBC) or metastatic/advanced breast cancer (MBC)

	1st diagnosis PBC followed by MBC (n = 95)	1st diagnosis MBC (n = 48)	Combined (n = 143)
Age (years)
(mean; sd)	53.12 (8.78)	48.71 (9.38)	51.64 (9.19)
Min–max range	31–77	28–69	28–77
Ethnicity
White	86 (91%)	42 (88%)	128 (90%)
Other	9 (9%)	6 (12%)	15 (10%)
How long living with MBC?
< 1 year	26 (27%)	17 (35%)	43 (30%)
1–2 years	36 (38%)	10 (21%)	46 (32%)
> 2 years	33 (35%)	21 (44%)	54 (38%)
Highest educational level
No certificates	3 (3%)	-	3 (2%)
O Levels/GCSE	16 (17%)	11 (23%)	27 (19%) 19 (13%)
A Levels	14 (15%)	5 (10%)
Vocational	15 (16%)	7 (15%)	22 (15%)
University degree	36 (38%)	16 (33%)	52 (37%)
Post grad degree	11 (11%)	9 (19%)	20 (14%)
Marital status
Married/partner	78 (82%)	39 (81%)	117 (82%)
Not partnered	17 (18%)	9 (19%)	26 (18%)
Main support
Spouse/partner	66 (70%)	34 (71%)	100 (70%)
Child	8 (8%)	1 (2%)	9 (6%)
Parent	3 (3%)	1 (2%)	4 (3%)
Sibling	5 (5%)	2 (4%)	7 (5%)
Friend	11 (12%)	7 (15%)	18 (13%)
None	2 (2%)	3 (6%)	5 (3%)
Employment Status
Not in paid employment	12 (13%)	7 (15%)	19 (13%)
Full/part time/self-employed	30 (32%)	19 (40%)	49 (34%)
Retired	20 (21%)	3 (6%)	23 (16%)
Medically retired	15 (15%)	6 (13%)	21 (14%)
Long-term sick leave	18 (19%)	13 (27%)	31 (22%)
Current treatment*
Surgery	4 (4%)	7(15%)	11 (8%)
Radiotherapy	6 (6%)	6 (13%)	12 (8%)
Chemotherapy (paclitaxel, carboplatin, capecitabine)	38 (40%)	8 (17%)	46 (32%)
Endocrine therapy (anastrazole, exemestane, fulvestrant, letrozole, tamoxifen)	42 (44%)	28 (58%)	70 (49%)
Targeted therapy (abemaciclib, everolimus, palbociclib, ribociclib, trastuzumab)	49 (51%)	34 (71%)	83 (58%)
Immunotherapy (atezolizumbab, pembrolizumab)	14 (15%)	2 (4%)	16 (11%)
Clinical trial	10 (11%)	4 (8%)	14 (10%)
None	6 (6%)	4 (8%)	10 (7%)

^*Can be on combination of treatments